[논문]특발성 폐섬유증의 통합의료 협진 모델 개발을 위한 의료진 및 환자 대상 설문조사 연구

박지원; 이범준; 신정원; 진수현; 양정민; 김수덕; 김관일; 최혜숙; 정희재

doi:10.22246/jikm.2023.44.3.366

특발성 폐섬유증의 통합의료 협진 모델 개발을 위한 의료진 및 환자 대상 설문조사 연구
Research for the Development of an Integrated Medical System for Idiopathic Pulmonary Fibrosis: Based on an Analysis of Questionnaire Survey in Doctor and Patient Groups 원문보기

대한한방내과학회지 = The journal of internal Korean medicine, v.44 no.3, 2023년, pp.366 - 386

박지원 (경희대학교 대학원 임상한의학과 폐계내과학교실) , 이범준 (경희대학교 대학원 임상한의학과 폐계내과학교실) , 신정원 (경희대학교 대학원 임상한의학과 폐계내과학교실) , 진수현 (경희대학교 대학원 임상한의학과 폐계내과학교실) , 양정민 (경희대학교 대학원 임상한의학과 폐계내과학교실) , 김수덕 (경희대학교 대학원 임상한의학과 폐계내과학교실) , 김관일 (경희대학교 대학원 임상한의학과 폐계내과학교실) , 최혜숙 (경희의료원 내과) , 정희재 (경희대학교 대학원 임상한의학과 폐계내과학교실)

Abstract ▼ AI-Helper

Objective: In this study, a questionnaire survey was conducted for doctors and patients to obtain basic data necessary for the development of an integrated medical system for idiopathic pulmonary fibrosis (IPF). Methods: Questionnaires were developed separately for doctors and patients through an expert group meeting. The survey subjects were recruited online and offline, and finally, responses from 231 doctors and 59 patients were used for statistical analysis. Results: The most important parts in the treatment of IPF for both doctors and patients were the "improvement of respiratory symptoms," "improvement of quality of life," and "prevention of disease progression." Antifibrotic agents were prescribed at a high rate, and 100% of the specialists in Western medicine (WM) and 45.8% of patients reported experiencing side effects. As for the additional payment costs that patients considered as affordable for an integrated medical system, "under 50,000 won (about 38$)" was reported the most in both doctor and patient groups. With regard to the reasons for their reluctance to recommend an integrated medical system for IPF, specialists in WM responded highly to "uncertain evidence for treatment effectiveness." Regarding complementary and alternative medicine therapies that can be beneficial in patients with IPF, "lifestyle management," "diet management," "herb," "relaxation therapy," and "psychotherapy" were ranked high in both doctor and patient groups. Conclusions: In this study, a questionnaire survey on IPF was conducted to review actual treatment status, analyze shortcomings, and identify considerations for the development of an integrated medical system for IPF in the future.

주제어

표/그림 (12)

그림 Fig. 1. General characteristics of responders in doctor survey.
표 Table 1. Clinical Treatment Experience for IPF in Doctor Survey
그림 Fig. 2. The most important part in the treatment of IPF in doctor survey. IPF : idiopathic pulmonary fibrosis, QOL : quality of life, CT : computed tomography, FVC : forced vital capacity, 6MWT : six-minute walk test, DLCO : diffusing capacity for carbon monoxide
표 Table 2. Additional Cost and Optimal Start Time for Cooperative Medical System between WM and KM for IPF in Doctor Survey
그림 Fig. 3. Reasons for reluctance to recommend cooperative medical system between WM and KM for IPF in doctor survey. KM : Korean medicine, WM : Western medicine, IPF : idiopathic pulmonary fibrosis *1st+2nd
표 Table 3. Opinion on CAM for IPF in Doctor Survey
그림 Fig. 4. General characteristics of responders in patient survey. IPF : idiopathic pulmonary fibrosis
그림 Fig. 5. The most important part in the treatment of IPF in patient survey (1st+2nd+3rd) (%). IPF : idiopathic pulmonary fibrosis, QOL : quality of life *1st+2nd+3rd
표 Table 4. Clinical Treatment Experience for IPF in Patient Survey
표 Table 5. Additional Cost and Optimal Start Time for Cooperative/integrated Medical System for IPF in Patient Survey
그림 Fig. 6. Opinion on cooperative/integrated medical system for IPF in patient survey. IPF : idiopathic pulmonary fibrosis, WM : Western medicine, KM : Korean medicine, CAM : complementary and alternative medicine
표 Table 6. Opinion on CAM for IPF in Patient Survey

참고문헌 (31)

King Jr TE, Pardo A, Selman M. Idiopathic？pulmonary fibrosis. The Lancet 2011;378(9807):1949-61.
Richeldi L, Collard HR, Jones MG. Idiopathic？pulmonary fibrosis. The Lancet 2017;389(10082):1941-52.
Raghu G, Amatto VC, Behr J, Stowasser S.？Comorbidities in idiopathic pulmonary fibrosis？patients: a systematic literature review. European？Respiratory Journal 2015;46(4):1113-30.

상세보기
Khor YH, Ng Y, Barnes H, Goh NSL, McDonald？CF, Holland AE. Prognosis of idiopathic pulmonary？fibrosis without anti-fibrotic therapy: a systematic？review. European Respiratory Review 2020;29(157):190158.
Kim SW, Myong JP, Yoon HK, Koo JW, Kwon？SS, Kim YH. Health care burden and medical？resource utilisation of idiopathic pulmonary fibrosis？in Korea. Int J Tuberc Lung Dis 2017;21(2):230-5.
Zaman T, Lee JS. Risk factors for the development？of idiopathic pulmonary fibrosis: A review. Curr？Pulmonol Rep 2018;7(4):118-25.
Cox IA, Borchers Arriagada N, de Graaff B, Corte？TJ, Glaspole I, Lartey S, et al. Health-related？quality of life of patients with idiopathic pulmonary？fibrosis: a systematic review and meta-analysis.？European Respiratory Review 2020;29(158):200154.

상세보기
Gao J, Kalafatis D, Carlson L, Pesonen IH, Li？CX, Wheelock A, et al. Baseline characteristics？and survival of patients of idiopathic pulmonary？fibrosis: a longitudinal analysis of the Swedish？IPF Registry. Respiratory research 2021;22(1):40.

상세보기
Noble PW, Albera C, Bradford WZ, Costabel U,？Du Bois RM, Fagan EA, et al. Pirfenidone for？idiopathic pulmonary fibrosis: analysis of pooled？data from three multinational phase 3 trials.？European Respiratory Journal 2016;47(1):243-53.

상세보기
Lancaster L, Crestani B, Hernandez P, Inoue？Y, Wachtlin D, Loaiza L, et al. Safety and？survival data in patients with idiopathic？pulmonary fibrosis treated with nintedanib:？pooled data from six clinical trials. BMJ Open？Respiratory Research 2019;6(1):e000397.

상세보기
Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche？J, Prasse A, et al. Health related quality of？life in patients with idiopathic pulmonary fibrosis？in clinical practice: insights-IPF registry. Respiratory？research 2017;18(1):139.
Kim ES, Keating GM. Pirfenidone: a review of？its use in idiopathic pulmonary fibrosis. Drugs？2015;75(2):219-30.
Margaritopoulos GA, Trachalaki A, Wells AU,？Vasarmidi E, Bibaki E, Papastratigakis G, et al.？Pirfenidone improves survival in IPF: results？from a real-life study. BMC pulmonary medicine？2018;18(1):177.
Cohen MH. Complementary and integrative medical？therapies, the FDA, and the NIH: definitions？and regulation. Dermatologic therapy 2003;16(2):77-84.

상세보기
Ji K, Ma J, Wang L, Li N, Dong S, Shi L.？Efficacy and safety of traditional Chinese？medicine in idiopathic pulmonary fibrosis: a？meta-analysis. Evidence-Based Complementary？and Alternative Medicine 2020;2020:1752387.

상세보기
Kalnins P, Brucker M, Spears D. Prolonged？Survival in a Patient with Idiopathic Pulmonary？Fibrosis Receiving Acupuncture and DHEA-Promoting Herbs with Conventional Management:？A Case Report. The Permanente Journal 2019;23:18-074.
Li B, Zhang Y, Yang QM. Umbilical moxibustion？for patients with idiopathic pulmonary fibrosis？complicated with gastroesophageal reflux of？lung-spleen qi deficiency. Chinese Acupuncture？& Moxibustion 2019;39(3):241-5.
Yu X, Li X, Wang L, Liu R, Xie Y, Li S, et al.？Pulmonary rehabilitation for exercise tolerance？and quality of life in IPF patients: a systematic？review and meta-analysis. BioMed research？international 2019;2019:8498603.

상세보기
Guler SA, Lindell KO, Swigris J, Ryerson CJ.？Nondrug Treatments for Idiopathic Pulmonary？Fibrosis: IPF Part 3. American journal of？respiratory and critical care medicine 2021;203(4):P10-P11.

상세보기
Mercader-Barcelo J, Truyols-Vives J, Rio C,？Lopez-Safont N, Sala-Llinas E, Chaplin A.？Insights into the role of bioactive food ingredients？and the microbiome in idiopathic pulmonary？fibrosis. International Journal of Molecular Sciences？2020;21(17):6051.
Duck A, Pigram L, Errhalt P, Ahmed D, Chaudhuri？N. IPF Care: a support program for patients？with idiopathic pulmonary fibrosis treated with？pirfenidone in Europe. Advances in therapy？2015;32(2):87-107.
Lee HY, Lee DH, Lee GE, Kim JH, Kim HM,？Kim NK. Survey on the satisfaction and demand？of healthcare providers who participated in a？collaborative first-stage pilot project between？Korean medicine and western medicine. Journal？of physiology & pathology in Korean Medicine？2018;32(2):134-40.
Li M, Wu R, Zhao Y, Li L, Li G, Liu S, et al.？Chinese Herbal Medicine for Idiopathic Pulmonary？Fibrosis: An Overview of Systematic Review.？Alternative Therapies in Health and Medicine？2023:AT8195.
Kim Y, Lee Y, Yoon S, Huh J. Nutritional？factors affecting the mortality in patients with？chronic lung disease. Current Developments in？Nutrition 2020;4(Supplement_2):41.
Volpato E, Banfi P, Rogers SM, Pagnini F.？Relaxation techniques for people with chronic？obstructive pulmonary disease: a systematic？review and a meta-analysis. Evidence-Based？Complementary and Alternative Medicine 2015;2015:628365.

상세보기
Choi WI. Current and future treatment for？idiopathic pulmonary fibrosis. Journal of the？Korean Medical Association 2021;64(4):256-63.
Shimizu Y, Shimoyama Y, Kawada A, Kusano M,？Hosomi Y, Sekiguchi M, et al. Gastrointestinal？symptoms in idiopathic pulmonary fibrosis？patients treated with pirfenidone and herbal？medicine. Journal of Biological Regulators and？Homeostatic Agents 2014;28(3):433-42.
Park JE, Kwon SM. Determinants of the utilization？of oriental medical services by the elderly. The？Journal of Korean Medicine 2011;32(1):97-108.
Vainshelboim B, Oliveira J, Izhakian S, Unterman？A, Kramer MR. Lifestyle Behaviors and Clinical？Outcomes in Idiopathic Pulmonary Fibrosis.？Respiration 2018;95(1):27-34.

상세보기
Poswal FS, Russell G, Mackonochie M, MacLennan？E, Adukwu EC, Rolfe V. Herbal teas and their？health benefits: a scoping review. Plant Foods？for Human Nutrition 2019;74(3):266-76.
Van Manen M, Kreuter M, Van Den Blink B,？Oltmanns U, Baroke E, Palmowski K, et al.？What patients with pulmonary fibrosis and？their partners really think; live patient and？partner survey on pulmonary fibrosis in the？netherlands and germany. A41. Here there and？everywhere: ILD observational studies: American？Thoracic Society 2015;191:A1591.

저자의 다른 논문 :

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증